Caligiuri Appointed President and Physician-in-Chief of City of Hope Medical Center

Michael A. Caligiuri, MD, has been appointed president and physician-in-chief of the City of Hope National Medical Center, a position which will go into effect in February 2018.

Michael A. Caligiuri, MD

Michael A. Caligiuri, MD, has been appointed president and physician-in-chief of the City of Hope National Medical Center, a position which will go into effect in February 2018. He comes The Ohio State University Comprehensive Cancer Center where he was the director of the center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; additionally, Caligiuri is the current president of the American Association for Cancer Research (AACR), serving from April 2017 through April 2018.

“This is an extraordinary time in cancer research and care. Every day brings exciting new discoveries and innovations, and City of Hope is at the forefront of groundbreaking work that will define new standards of care,” Robert W. Stone, City of Hope’s president and CEO, said in a statement. “Dr Caligiuri is an exceptional and accomplished leader who will join and lead an extraordinary group of talented individuals singularly focused on eradicating cancer and diabetes. As I have come to know him, I have been struck by his innovative approach to science, high degree of humility and dedication to serving patients in need—all of which fit perfectly with City of Hope.”

As president of the City of Hope National Medical Center, Caligiuri will be responsible for bringing new state-of-the-art research to City of Hope and translating it into practice for cancer care, and for optimizing the quality of the patient care system.

Actively involved with AACR since 1990, Caligiuri has served on the board of directors from 2013-2016 and as chairperson of the Publications Committee since 2013. He has held positions with numerous other committees and editorial boards of reputable publications as well.

“On behalf of the American Association for Cancer Research, I wish to extend our sincere congratulations to President Michael Caligiuri,” Margaret Foti, PhD, MD (hc), CEO of the AACR, said in a statement. “Dr Caligiuri is a distinguished physician-scientist and highly esteemed leader, not only for the AACR, but for the cancer community at large. His dedication to accelerating the pace of discovery and its translation to the clinic will be invaluable to City of Hope, and in his new position he will be able to make a difference for humankind.”

His immunology work is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. Over 1500 cancer patients have been treated on clinical protocols that have originated from the Caligiuri laboratory.

He has been recognized with numerous honors and awards throughout his career, including the Director’s Service Award and the MERIT Award from the National Cancer Institute, the John Wayne Clinical Research Award from the Society of Surgical Center. He is an elected fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Alpha Omega Honor Medical Society, as well as an elected member of the Association of American Physicians and the American Society for Clinical Investigation.

“City of Hope is an incredible institution with an amazing history of innovation,” Caligiuri said in a statement. “I have many friends and colleagues at City of Hope and I am incredibly excited about the organization’s vision. I share that vision and excitement for the role City of Hope will play in changing the global landscape of cancer care.”

Caligiuri received his bachelor’s degree from the State University of New York at Buffalo. He later received his master’s and medical degrees from Stanford University in Stanford, California. His residency in internal medicine was completed at Brigham and Women’s Hospital at Harvard Medical School and he completed his fellowship in medical oncology, bone transplantation, and immunology at Dana-Farber Cancer Institute in Boston, Massachusetts.